Efficacy of phytol-derived diterpenoid immunoadjuvants over alum in shaping the murine host's immune response to Staphylococcus aureus

Chowdhury, Roshni Roy; Fitch, Richard W.; Ghosh, S.

doi:10.1016/j.vaccine.2012.12.069

Cited by 11 publications

(10 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-teratogenic activity in female mice Phytol at 500 mg/kg; Phytanic acid at 100 mg/kg (Arnhold et al, 2002) Phytanol and phytanyl chloride 44 mg per mice (i.p.) Mice exposed to S. aureus 44 mg (Roy Chowdhury et al, 2013) Phytanol, phytanyl amine Phytanol: 40 mg (i.p.) Phytanyl amine: 5 mg (i.p.…”

Section: A N U S C R I P Tmentioning

confidence: 99%

Phytol: A review of biomedical activities

Islam

Ali

Uddin

et al. 2018

Food and Chemical Toxicology

269

151

View full text Add to dashboard Cite

Phytol (PYT) is a diterpene member of the long-chain unsaturated acyclic alcohols. PYT and some of its derivatives, including phytanic acid (PA), exert a wide range of biological effects. PYT is a valuable essential oil (EO) used as a fragrance and a potential candidate for a broad range of applications in the pharmaceutical and biotechnological industry. There is ample evidence that PA may play a crucial role in the development of pathophysiological states. Focusing on PYT and some of its most relevant derivatives, here we present a systematic review of reported biological activities, along with their underlying mechanism of action. Recent investigations with PYT demonstrated anxiolytic, metabolism-modulating, cytotoxic, antioxidant, autophagy- and apoptosis-inducing, antinociceptive, anti-inflammatory, immune-modulating, and antimicrobial effects. PPARs- and NF-κB-mediated activities are also discussed as mechanisms responsible for some of the bioactivities of PYT. The overall goal of this review is to discuss recent findings pertaining to PYT biological activities and its possible applications.

show abstract

Section: A N U S C R I P Tmentioning

confidence: 99%

Phytol: A review of biomedical activities

Islam

Ali

Uddin

et al. 2018

Food and Chemical Toxicology

269

151

View full text Add to dashboard Cite

show abstract

“…Can the Th17 response be prolonged/enhanced by unique adjuvants that stimulate CD27/TRAFS? Phytol‐based terpenoids, phytanol (PHIS‐01) and phytanuyl Cl (PCl), have been shown to improve Th17/IL‐17 responses . Th17 immunity has been implicated in mucosal immunity against Clostridium difficile ; hence, one might speculate that it also might be valuable in decreasing mucosal colonization, which might prevent vaginal colonization and toxic shock syndrome or reduce nasal carriage .…”

Section: Future For a Staphylococcus Aureus Vaccinementioning

confidence: 99%

“…Can the Th17 response be prolonged/enhanced by unique adjuvants that stimulate CD27/TRAFS? Phytol-based terpenoids, phytanol (PHIS-01) and phytanuyl Cl (PCl), have been shown to improve Th17/IL-17 responses [28,74,75]. Th17 immunity has been implicated in mucosal immunity ª2014 The Authors Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl.…”

Section: Future For a Staphylococcus Aureus Vaccinementioning

confidence: 99%

“…Th17 immunity has been implicated in mucosal immunity ª2014 The Authors Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20 (Suppl. 5), [66][67][68][69][70][71][72][73][74][75] against Clostridium difficile [76]; hence, one might speculate that it also might be valuable in decreasing mucosal colonization, which might prevent vaginal colonization and toxic shock syndrome or reduce nasal carriage [92]. Care must be exercised in developing a robust Th17 response because this arm of the immune system has been implicated in autoimmune diseases [77] and Th17 was induced by the IsdB (V710) vaccine [32], which was associated with an increase in multi-organ failure during S. aureus infections [2].…”

Section: Future For a Staphylococcus Aureus Vaccinementioning

confidence: 99%

See 1 more Smart Citation

Where does a Staphylococcus aureus vaccine stand?

Fowler

Proctor

2014

Clinical Microbiology and Infection

209

176

View full text Add to dashboard Cite

In this review, we examine the current status of Staphylococcus aureus vaccine development and the prospects for future vaccines. Examination of the clinical trials to date show that murine models have not predicted success in humans for active or passive immunization. A key factor in the failure to develop a vaccine to prevent S. aureus infections comes from our relatively limited knowledge of human protective immunity. More recent reports on the elements of the human immune response to staphylococci are analysed. In addition, there is some controversy concerning the role of antibodies for protecting humans, and these data are reviewed. From a review of the current state of understanding of staphylococcal immunity, a working model is proposed. Some new work has provided some initial candidate biomarker(s) to predict outcomes of invasive infections and to predict the efficacy of antibiotic therapy in humans. We conclude by looking to the future through the perspective of lessons gleaned from the clinical vaccine trials.

show abstract

“…Although vaccination is a common practice to control infectious diseases, yet there is no licensed vaccine available till date to S. aureus infections. This failure is largely due to the multiple arrays of virulence factors secreted by the organism, evasion of the host's immune system and leukolytic toxins which lyse the phagocytic cells (Roy Chowdhury et al, 2013;Otto, 2010). Staphylococcal enterotoxins (SEs) and toxic shock syndrome toxin (TSST) are the Pyrogenic Toxin Super Antigens (PTSAs) responsible for toxic shock syndrome in deep tissues and vaginal tissues respectively (Poli et al, 2002).…”

Section: Introductionmentioning

confidence: 99%